163 related articles for article (PubMed ID: 8884349)
1. Proliferation, ploidy and prognosis in uterine smooth muscle tumours.
Jeffers MD; Oakes SJ; Richmond JA; Macaulay EM
Histopathology; 1996 Sep; 29(3):217-23. PubMed ID: 8884349
[TBL] [Abstract][Full Text] [Related]
2. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
3. Deoxyribonucleic acid analysis by flow cytometry of uterine leiomyosarcomas and smooth muscle tumors of uncertain malignant potential.
Peters WA; Howard DR; Andersen WA; Figge DC
Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 1):1646-53; discussion 1653-4. PubMed ID: 1615971
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma.
Nordal RR; Kristensen GB; Kaern J; Stenwig AE; Pettersen EO; Tropé CG
Acta Oncol; 1995; 34(6):797-802. PubMed ID: 7576748
[TBL] [Abstract][Full Text] [Related]
5. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic comparison of leiomyoma and leiomyosarcoma.
Martin SA; Sears DL; Sebo TJ; Lohse CM; Cheville JC
Am J Surg Pathol; 2002 Mar; 26(3):292-300. PubMed ID: 11859200
[TBL] [Abstract][Full Text] [Related]
6. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology.
Layfield LJ; Liu K; Dodge R; Barsky SH
Arch Pathol Lab Med; 2000 Feb; 124(2):221-7. PubMed ID: 10656730
[TBL] [Abstract][Full Text] [Related]
7. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
[TBL] [Abstract][Full Text] [Related]
8. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors.
Chou FF; Eng HL; Sheen-Chen SM
Surgery; 1996 Feb; 119(2):171-7. PubMed ID: 8571202
[TBL] [Abstract][Full Text] [Related]
9. Uterine leiomyosarcomas and benign smooth muscle tumors: usefulness of nuclear DNA patterns studied by flow cytometry.
Tsushima K; Stanhope CR; Gaffey TA; Lieber MM
Mayo Clin Proc; 1988 Mar; 63(3):248-55. PubMed ID: 3343869
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of biological potential of smooth muscle tumours.
Miettinen M; Fetsch JF
Histopathology; 2006 Jan; 48(1):97-105. PubMed ID: 16359541
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators.
Malmström H; Schmidt H; Persson PG; Carstensen J; Nordenskjöld B; Simonsen E
Gynecol Oncol; 1992 Feb; 44(2):172-7. PubMed ID: 1544595
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.
Zhai YL; Nikaido T; Toki T; Shiozawa A; Orii A; Fujii S
Br J Cancer; 1999 Jul; 80(10):1658-64. PubMed ID: 10408415
[TBL] [Abstract][Full Text] [Related]
13. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.
Ip PP; Cheung AN
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):691-704. PubMed ID: 21865091
[TBL] [Abstract][Full Text] [Related]
14. Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects.
Waldmann J; Stachs A; Terpe H; Stropahl G; Makovitzky J
Anticancer Res; 2005; 25(3A):1559-65. PubMed ID: 16033061
[TBL] [Abstract][Full Text] [Related]
15. Sinonasal smooth muscle cell tumors: a clinicopathologic and immunohistochemical analysis of 12 cases with emphasis on the low-grade end of the spectrum.
Huang HY; Antonescu CR
Arch Pathol Lab Med; 2003 Mar; 127(3):297-304. PubMed ID: 12653572
[TBL] [Abstract][Full Text] [Related]
16. DNA ploidy, S-phase fraction and mitotic indices as prognostic predictors of female breast cancer.
Lipponen P; Papinaho S; Eskelinen M; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(5):1533-8. PubMed ID: 1444217
[TBL] [Abstract][Full Text] [Related]
17. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis.
D'Angelo E; Espinosa I; Ali R; Gilks CB; Rijn Mv; Lee CH; Prat J
Gynecol Oncol; 2011 May; 121(2):328-33. PubMed ID: 21316747
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma.
Victorzon M; Roberts PJ; Haglund C; von Boguslawsky K; Nordling S
Oncology; 1996; 53(3):182-91. PubMed ID: 8643219
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of DNA ploidy in a total population of uterine sarcomas.
Kildal W; Abeler VM; Kristensen GB; Jenstad M; Thoresen SØ; Danielsen HE
Ann Oncol; 2009 Jun; 20(6):1037-41. PubMed ID: 19201782
[TBL] [Abstract][Full Text] [Related]
20. Uterine smooth-muscle tumors of uncertain malignant potential.
Peters WA; Howard DR; Andersen WA; Figge DC
Obstet Gynecol; 1994 Jun; 83(6):1015-20. PubMed ID: 8190416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
